Zobrazit v EDS

Bioelectrical impedance analysis as a clinical marker of health status in adult patients with benign gastrointestinal disease:A systematic review

Uloženo v:
Podrobná bibliografie
Název: Bioelectrical impedance analysis as a clinical marker of health status in adult patients with benign gastrointestinal disease:A systematic review
Autoři: Quist, Josephine Reinert, Rud, Charlotte Lock, Brantlov, Steven, Ward, Leigh C, Dahl Baunwall, Simon Mark, Hvas, Christian Lodberg
Zdroj: Quist, J R, Rud, C L, Brantlov, S, Ward, L C, Dahl Baunwall, S M & Hvas, C L 2024, 'Bioelectrical impedance analysis as a clinical marker of health status in adult patients with benign gastrointestinal disease : A systematic review', Clinical Nutrition ESPEN, vol. 59, pp. 387-397. https://doi.org/10.1016/j.clnesp.2023.12.145
Rok vydání: 2024
Sbírka: Aarhus University: Research
Témata: Adult, Biomarkers, Body Composition/physiology, Electric Impedance, Gastrointestinal Diseases/diagnosis, Health Status, Humans, Prospective Studies, Nutritional assessment, Bioelectrical impedance, Impedance, Gastrointestinal disease
Popis: BACKGROUND: Body composition reflects nutritional status, disease status and progression, and treatment responses. Mounting evidence supports the use of bioelectrical impedance analysis (BIA) as a non-invasive tool to assess body composition. Patients with benign gastrointestinal (GI) disease experience disease-related alterations in their body composition, and bioimpedance outcomes in patients with benign GI diseases have not previously been summarized. We aimed to evaluate BIA as a clinical body composition marker for benign GI diseases and describe its association with physical health status. METHODS: We systematically searched PubMed, Scopus, Web of Science, Embase, and CINAHL from inception to October 2023 (PROSPERO registration: CRD42021265866). Of 971 screened studies, 26 studies were included in the final analysis, comprising a total of 2398 adult patients with benign GI disease. The main outcome was raw impedance data. RESULTS: The most frequently reported BIA outcome was phase angle (PhA) (reported in 18 of 26 studies), followed by fat-free-mass (FFM) (reported in 13 of 26 studies). The consensus view of the included studies illustrates that BIA can be a useful tool for evaluating body composition in patients with benign GI diseases, and low PhA and FFM were associated with increased nutritional risk, abnormal physical characteristics, and increased mortality risk. CONCLUSION: To fully utilize BIA as a clinical marker of health in patients with benign GI disease, standardized protocols specific to this population are needed and prospective studies testing cut-offs and ranges, accuracy, and other raw BIA parameters for classifying disease status.
Druh dokumentu: article in journal/newspaper
Popis souboru: application/pdf
Jazyk: English
DOI: 10.1016/j.clnesp.2023.12.145
Dostupnost: https://pure.au.dk/portal/en/publications/fa39dcd6-9dfe-440e-bfba-e40ec5d214b9
https://doi.org/10.1016/j.clnesp.2023.12.145
https://pure.au.dk/ws/files/384259926/1-s2.0-S2405457723023707-main.pdf
http://www.scopus.com/inward/record.url?scp=85181807619&partnerID=8YFLogxK
Rights: info:eu-repo/semantics/openAccess
Přístupové číslo: edsbas.B5CF1998
Databáze: BASE
Popis
Abstrakt:BACKGROUND: Body composition reflects nutritional status, disease status and progression, and treatment responses. Mounting evidence supports the use of bioelectrical impedance analysis (BIA) as a non-invasive tool to assess body composition. Patients with benign gastrointestinal (GI) disease experience disease-related alterations in their body composition, and bioimpedance outcomes in patients with benign GI diseases have not previously been summarized. We aimed to evaluate BIA as a clinical body composition marker for benign GI diseases and describe its association with physical health status. METHODS: We systematically searched PubMed, Scopus, Web of Science, Embase, and CINAHL from inception to October 2023 (PROSPERO registration: CRD42021265866). Of 971 screened studies, 26 studies were included in the final analysis, comprising a total of 2398 adult patients with benign GI disease. The main outcome was raw impedance data. RESULTS: The most frequently reported BIA outcome was phase angle (PhA) (reported in 18 of 26 studies), followed by fat-free-mass (FFM) (reported in 13 of 26 studies). The consensus view of the included studies illustrates that BIA can be a useful tool for evaluating body composition in patients with benign GI diseases, and low PhA and FFM were associated with increased nutritional risk, abnormal physical characteristics, and increased mortality risk. CONCLUSION: To fully utilize BIA as a clinical marker of health in patients with benign GI disease, standardized protocols specific to this population are needed and prospective studies testing cut-offs and ranges, accuracy, and other raw BIA parameters for classifying disease status.
DOI:10.1016/j.clnesp.2023.12.145